---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-26-000033"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:44:05.892061+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50

## Summary
- Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.
- Adjusted EPS $0.54 vs $0.41; adjusted gross margin 64.1% vs 62.2%. Adjusted EBITDA $76.2M (19.4% rev).
- Specialty Surgery rev $283.1M (+0.9% rep, -0.6% organic); Tissue Reconstruction $108.8M (+6.7% rep, +6.4% organic).
- Reaffirms FY rev guidance $1.662B-$1.702B; raises adj. EPS guidance to $2.40-$2.50 from $2.30-$2.40.
- Braintree facility on track to begin SurgiMend production by end of June for Q4 launch; PriMatrix/Durepair returning.

## SEC filing metadata
- accession: 0000917520-26-000033
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/0000917520-26-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/iart-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-26-000033
- JSON: https://secwatch.observer/filing/0000917520-26-000033.json
- Plain text: https://secwatch.observer/filing/0000917520-26-000033.txt

## Key facts
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported the first quarter ending March 31, 2026 results: revenue $391.9 million, net income $(4.6) million, EPS $(0.06) per diluted share. Guidance raised.
  - Period: the first quarter ending March 31, 2026
  - Revenue: $391.9 million
  - Net income: $(4.6) million
  - EPS: $(0.06) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: Total reported revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 55.4%, compared to 50.8% in the first quarter of 2025. Adjusted gross margin was 64.1%, compared to 62.2% in the prior year. Adjusted EBITDA for the first quarter of 2026 was $76.2 million, or 19.4% of revenue, compared to $63.6 million, or 16.6% of revenue, in the prior year. The Company reported a GAAP net loss of $(4.6) million, or $(0.06) per diluted share, in the first quarter of 2026, compared to GAAP net loss of $(25.3) million, or $(0.33) per diluted share, in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/0000917520-26-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.